Skip to main content
Fig. 5 | BMC Nephrology

Fig. 5

From: The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis

Fig. 5

Serum phosphate and phosphate binder pill burden during baseline and sucroferric oxyhydroxide follow-up (Q1–4). Abbreviations: mSFOH, PB-naïve patients treated with SFOH monotherapy; PB, phosphate binder; PB + SFOH, PB-pretreated patients who added SFOH to another PB; PB → SFOH, PB-pretreated patients switched to SFOH monotherapy; pts, patients; SFOH, sucroferric oxyhydroxide; sP, serum phosphate. Mean values are shown in the table. *p < 0.05; ***p < 0.0001 (vs baseline)

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us